Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belimumab for the treatment of frequently relapsing nephrotic syndrome open label phase II trial. (BELNEPH STUDY BELNEPH: Studio prospettico aperto di fase II sull'uso del Belimumab per il trattamento di pazienti pediatrici affetti da sindrome nefrosica corticosensibile a frequenti recidive)

Trial Profile

Belimumab for the treatment of frequently relapsing nephrotic syndrome open label phase II trial. (BELNEPH STUDY BELNEPH: Studio prospettico aperto di fase II sull'uso del Belimumab per il trattamento di pazienti pediatrici affetti da sindrome nefrosica corticosensibile a frequenti recidive)

Not stated
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Belimumab (Primary)
  • Indications Nephrotic syndrome
  • Focus Adverse reactions
  • Acronyms BELNEPH
  • Most Recent Events

    • 12 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top